Well. After reading the announcements last night that Hopper and Hains have participated in the latest SPP, I would not be holding any hope of receiving any news of results. However - the Company in my opinion would definitely be in possession of key market sensitive results.
We really should be reading updates on the following:
1. CORE NK ADVENT trial: Six patients dosed commencing 5th Feb 2024 and all dosed by 29/07/24. No efficacy results - even after 15 months.
2. CORE-NK Frontline Trial: CHM announced one patient dosed (sometime between 16/12/24 and 31/03/25), but has released no safety or efficacy results.
3. Case Western Reserve Trial: CHM announced a “complete response” after 28 days for one patient 07/10/24. No updates for SEVEN months.
4. CDH-17 Trial: Patient 2 was dosed over 90 days ago, Patient 3 over 60 days ago. Both milestones would have been achieved by 31/03/25. CHM has released no 60- or 90-day efficacy updates.
CHM Price at posting:
0.5¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)